Anna V Subramaniam1, Susan A Weston2, Jill M Killian2, Phillip J Schulte2, Veronique L Roger3,4, Margaret M Redfield3, Saul B Blecker5, Shannon M Dunlay3,6. 1. Department of Medicine (A.V.S.), Mayo Clinic, Rochester, MN. 2. Department of Quantitative Health Sciences (S.A.W., J.M.K., P.J.S.), Mayo Clinic, Rochester, MN. 3. Department of Cardiovascular Medicine (V.L.R., M.M.R., S.M.D.), Mayo Clinic, Rochester, MN. 4. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (V.L.R.). 5. Department of Population Health and Medicine, New York University Langone (S.B.B.). 6. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (S.M.D.), Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Some patients with heart failure (HF) will go on to develop advanced HF, characterized by severe HF symptoms despite attempts to optimize medical therapy. The goals of this study were to examine the risk of developing advanced HF in patients with newly diagnosed HF, identify risk factors for developing advanced HF, and evaluate the impact of advanced HF on outcomes. METHODS: This was a population-based, retrospective cohort study of Olmsted County, Minnesota, residents with a new clinical diagnosis of HF between 2007 and 2017. Risk factors for the development of advanced HF (2018 European Society of Cardiology criteria) were examined using cause-specific Cox proportional hazard regression models. The associations of development of advanced HF with risks of hospitalization and mortality were examined using the Andersen-Gill and Cox models, respectively. RESULTS: There were 4597 residents with incident HF from 2007 to 2017. The cumulative incidence of advanced HF was 11.5% (95% CI, 10.5%-12.5%) at 6 years after incident HF diagnosis overall and was 14.4% (95% CI, 12.3%-16.9%), 11.4% (95% CI, 8.9%-14.6%), and 11.7% (95% CI, 10.3%-13.2%) in patients with incident HF with reduced, mildly reduced, and preserved ejection fraction, respectively. Key demographics, comorbidities, and echocardiographic characteristics were independently associated with the development of advanced HF. Development of advanced HF was associated with increased risks of all-cause hospitalization (adjusted hazard ratio, 3.0 [95% CI, 2.7-3.4]; P<0.001), HF hospitalization (hazard ratio, 10.2 [95% CI, 8.7-12.1]), all-cause mortality (hazard ratio, 5.0 [95% CI, 4.5-5.6]; P<0.001), and cardiovascular mortality (hazard ratio, 7.8 [95% CI, 6.7-9.1]). CONCLUSIONS: In this population-based study, development of advanced HF was common and was associated with markedly increased morbidity and mortality.
BACKGROUND: Some patients with heart failure (HF) will go on to develop advanced HF, characterized by severe HF symptoms despite attempts to optimize medical therapy. The goals of this study were to examine the risk of developing advanced HF in patients with newly diagnosed HF, identify risk factors for developing advanced HF, and evaluate the impact of advanced HF on outcomes. METHODS: This was a population-based, retrospective cohort study of Olmsted County, Minnesota, residents with a new clinical diagnosis of HF between 2007 and 2017. Risk factors for the development of advanced HF (2018 European Society of Cardiology criteria) were examined using cause-specific Cox proportional hazard regression models. The associations of development of advanced HF with risks of hospitalization and mortality were examined using the Andersen-Gill and Cox models, respectively. RESULTS: There were 4597 residents with incident HF from 2007 to 2017. The cumulative incidence of advanced HF was 11.5% (95% CI, 10.5%-12.5%) at 6 years after incident HF diagnosis overall and was 14.4% (95% CI, 12.3%-16.9%), 11.4% (95% CI, 8.9%-14.6%), and 11.7% (95% CI, 10.3%-13.2%) in patients with incident HF with reduced, mildly reduced, and preserved ejection fraction, respectively. Key demographics, comorbidities, and echocardiographic characteristics were independently associated with the development of advanced HF. Development of advanced HF was associated with increased risks of all-cause hospitalization (adjusted hazard ratio, 3.0 [95% CI, 2.7-3.4]; P<0.001), HF hospitalization (hazard ratio, 10.2 [95% CI, 8.7-12.1]), all-cause mortality (hazard ratio, 5.0 [95% CI, 4.5-5.6]; P<0.001), and cardiovascular mortality (hazard ratio, 7.8 [95% CI, 6.7-9.1]). CONCLUSIONS: In this population-based study, development of advanced HF was common and was associated with markedly increased morbidity and mortality.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Carol Mitchell; Peter S Rahko; Lori A Blauwet; Barry Canaday; Joshua A Finstuen; Michael C Foster; Kenneth Horton; Kofo O Ogunyankin; Richard A Palma; Eric J Velazquez Journal: J Am Soc Echocardiogr Date: 2018-10-01 Impact factor: 5.251
Authors: Stuart J Pocock; Cono A Ariti; John J V McMurray; Aldo Maggioni; Lars Køber; Iain B Squire; Karl Swedberg; Joanna Dobson; Katrina K Poppe; Gillian A Whalley; Rob N Doughty Journal: Eur Heart J Date: 2012-10-24 Impact factor: 29.983
Authors: Yariv Gerber; Susan A Weston; Margaret M Redfield; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Jill M Killian; Véronique L Roger Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: F Zannad; S Briancon; Y Juilliere; P M Mertes; J P Villemot; F Alla; J M Virion Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao Journal: Circulation Date: 2020-01-29 Impact factor: 29.690
Authors: Shannon M Dunlay; Véronique L Roger; Jill M Killian; Susan A Weston; Philip J Schulte; Anna V Subramaniam; Saul B Blecker; Margaret M Redfield Journal: JACC Heart Fail Date: 2021-08-11 Impact factor: 12.544
Authors: Sei J Lee; Alan S Go; Karla Lindquist; Daniel Bertenthal; Kenneth E Covinsky Journal: Am J Public Health Date: 2008-05-29 Impact factor: 9.308
Authors: Alanna A Morris; Prateeti Khazanie; Mark H Drazner; Nancy M Albert; Khadijah Breathett; Lauren B Cooper; Howard J Eisen; Patrick O'Gara; Stuart D Russell Journal: Circulation Date: 2021-09-10 Impact factor: 29.690